US Solid Tumor Testing Market Size, Key Players, opportunities, and Growth Report (2022-2032)

[Tanzeel Obaid]

According to the American Cancer Society, Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells.” According to the National Cancer Institute (NCI), a solid tumor is defined as “an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer) or malignant (cancer).” In this study, considerations for solid tumors follow the definition of the National Cancer Institute. Examples include sarcomas, carcinomas, and lymphomas of the organs that are affected. Major solid tumors include breast cancer, prostate cancer, colorectal cancer, lung cancer, and melanoma, among others.

According to the American Cancer Society, the leading states with the highest estimated number of cancer cases in the U.S. in 2021 are California, Florida, and Texas. Other hotspots with an increasing number of cases in the country include New York, Pennsylvania, Illinois, and Ohio.

The increasing number of patients undergoing testing, the consistent evolution of technologies increasing the sensitivity of cancer diagnosis, and an overall approach toward precision medicine has created tremendous opportunities for solid tumor testing in the U.S. This has also resulted in decreasing death rates from cancer during the current decade when compared to the last decade.

U.S. Solid Tumor Testing Market Overview

The U.S. Solid Tumor Testing Market was estimated to be at $9,498.8 million in 2021, which is expected to grow with a CAGR of 6.19% during the forecast period 2022-2032 and reach $18,287.6 million by 2032.

The growth in the U.S. solid tumor testing market is expected to be driven by increasing awareness of early tumor diagnosis and tests along with the increasing geriatric population. Furthermore, increasing cancer incidences in the pediatric population.

Market Segmentation:

Segmentation 1: by Technology
Segmentation 2: by Cancer Type
Segmentation 3: by Type of Biomarker
Segmentation 4: by Application
Segmentation 5: by End User
Segmentation 6: by Region

Get a Free Sample Report - https://bit.ly/3CHcQMv

Some of the prominent established names in this market are:
• Abbott.
• ARUP Laboratories
• Bio-Rad Laboratories, Inc.
• Caris Life Sciences.
• F. Hoffmann-La Roche Ltd
• Genomic Testing Cooperative
• Guardant Health
• HTG Molecular Diagnostics, Inc.
• Illumina, Inc.
• Invitae Corporation
• Invivoscribe, Inc.
• Laboratory Corporation of America Holdings
• NanoString
• NeoGenomics Laboratories
• Opko Health, Inc.
• QIAGEN
• Quest Diagnostics Incorporated.
• Thermo Fisher Scientific, Inc.
• VYANTbio.

Detailed Report Overview at: https://bit.ly/42TW2MP